Cryptis

France-based TxCell and Switzerland’s Ferring International have partnered with Trizell Holding to further enhance the development of TxCell’s Ovasave to treat inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis.

The collaboration, option, development and license agreement between both companies for the product was assigned to Trizell, an affiliate member of the Dr Frederik Paulsen Foundation.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

TxCell CEO Damian Marron said: "Products at the forefront of innovation, such as TxCell’s personalised medicine, require expert and dedicated development teams.

"As such, TxCell’s lead product Ovasave for severe refractory Crohn’s disease will benefit enormously from the additional focus and expertise that Trizell will supply."

"The collaboration, option, development and license agreement between both companies for the product was assigned to Trizell, an affiliate member of the Dr Frederik Paulsen Foundation."

In December 2013, the Foundation’s affiliate Ferring signed an exclusive worldwide agreement with TxCell, receiving the option to be the commercialising entity for Ovasave to treat IBD, including Crohn’s disease and ulcerative colitis.

The deal is said to be worth €76m ($92.5m), which includes upfront and milestone payments, as well as royalties subject to the achievement of sales milestones, and is unchanged by the Trizell assignment.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Ferring International executive board president Michel Pettigrew said: "This assignment to the Foundation’s specialist company reinforces our increasing commitment to new products like Ovasave, which offer potential breakthroughs in the treatment for diseases with high unmet medical needs."

Dr Frederik established Trizell to provide specialist management and scientific and development expertise to advanced therapies, including cellular and gene therapies.

TxCell developed ASTrIA, a technology platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs).

Image: High magnification micrograph of cryptitis in a case of Crohn’s disease. Photo: courtesy of Nephron.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact